Headquarters: Hialeah Technology Center
Concept: Entopsis is developing an innovative molecular profiling platform that will allow people to diagnose themselves for diseases at home easily, cheaply and quickly using just a NuTec, a specialized glass slide the company developed, and an app on their smartphone. A liquid sample of blood, saliva or urine is placed on the glass slide, heated to cause changes in color and photographed with your smartphone or with a photo scanner. Then, the photo is uploaded through the corresponding app, which will deliver the diagnostic results through a cloud-based system in seconds.
Story: Entopsis founders Ian Cheong and Obdulio Piloto met while obtaining their doctorates at Johns Hopkins University School of Medicine and have been friends for 12 years. Since both had scientific medical backgrounds, they knew that they wanted to work together to create a technology that would help people in a significant way. Many people in developing countries lack access to life-saving diagnostic tests, mostly due to their high cost, invasiveness and the countries’ lack of advanced medical infrastructure, so Cheong and Piloto set out to create a diagnostic platform to tackle that problem.
Never miss a local story.
This is a testing technology that can be applied to almost any substance and across a range of industries such as food science, with food contamination and agriculture, with disease detection in livestock and for people to be tested for various diseases. Entopsis is the only company in Florida supported by the competitive Peter Thiel Foundation’s Breakout Labs.
Launched: January 2012
Management team: Obdulio Piloto, Ph.D., co-founder and CEO; Ian Cheong, Ph.D., co-founder; George Huang, Ph.D., CFA, chief financial officer; Tingjun Lei, Ph.D., lead scientist.
No. of employees: six
Financing: “We have invested $500,000 in the business to date, including self-funding, gifts and funding from Breakout Labs and other investors for the research and development phase,” Piloto said.
Recent milestones: Entopsis has significantly improved the capabilities of its novel machine-learning system, a process that took about five months. This breakthrough in technology now allows for a quicker and more accurate diagnosis, improving the overall product. In addition, their team has also made numerous improvements to the molecular binding surfaces on the NuTec, thus allowing for the capture and visualization of even more diverse biomarkers. Entopsis also just recently expanded manufacturing and laboratory space at the Hialeah Technology Center, allowing the company to run more tests on a variety of sample types without risk of cross contamination.
Biggest startup challenge: Funding and access to patient samples. “In order to test our platform across multiple industries, we need to partner with different beta testers in each field, such as the food industry, diagnostics, and bio defense, in order to identify problems and how NuTec can potentially solve them,” Piloto said. The company can develop a new diagnostic test in less than a week: “The challenge we are encountering, is gaining access to patient samples so that we can fully demonstrate the advantages of our technology.”
Next step: Finalizing the NuTec platform and developing tests for commercial use. “Right now, we have many different prototypes, so we want to take the best aspects of all prototypes and turn them into one platform to commercialize for public use, while making the testing as automated as possible,” Piloto said. “Once complete, we will offer the platform to beta-testers and further optimize before offering the platform to the consumer market. We are always looking for partners interested in co-developing tests with our team.”
Investor/mentor's view: “Breakout Labs looks for novel cutting-edge science with broad application. Entopsis is based on an entirely new way to analyze biomolecules that, if successful, could become the new paradigm for rapid molecular identification in contexts ranging from food safety to medicine,” said Lindy Fishburne, executive director of Breakout Labs, adding that Entopsis has overcome many development challenges.
“Because we fund many platform technologies, we see that our companies very often face a theoretical embarrassment of riches in choosing the right first application. The advice we give them is to go out and talk early and often with the potential customer to understand the pain points that the technology can solve and where the practical challenges would be in its integration into existing workflows or pipelines,” Fishburne said.